3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Solid Tumor
1
Leukemia
1
Interventions
Nivolumab
7
toripalimab
5
Injections
5
tislelizumab
3
pembrolizumab
3
spartalizumab
2
sintilimab
2
osimertinib
2
Paclitaxel
2
Ipilimumab
2
Gemcitabine
2
Cisplatin
2
Carboplatin
2
zimberelimab
1
ulocuplumab
1
sotorasib
1
famitinib
1
donafenib
1
cemiplimab
1
binimetinib
1
avelumab
1
atezolizumab
1
WW Domain-Containing Oxidoreductase
1
Taxes
1
SHR-1701
1
Oxaliplatin
1
N-benzhydryl-5-(2-(methylamino)propanamido)-3-(3-methylbutanoyl)-6-oxodecahydropyrrolo(1,2-a)(1,5)diazocine-8-carboxamide
1
LY-2157299
1
Immunotherapy, Adoptive
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Solid Tumor
×
ulocuplumab
×
Clear all
NCT02472977
2018-11-01
CXCessoR4
Bristol-Myers Squibb
Phase 1/2
Terminated
61 enrolled
11 charts